Ming Ouyang

571 total citations
28 papers, 337 citations indexed

About

Ming Ouyang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Ming Ouyang has authored 28 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 7 papers in Surgery. Recurrent topics in Ming Ouyang's work include Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (8 papers) and Metastasis and carcinoma case studies (3 papers). Ming Ouyang is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Lung Cancer Research Studies (8 papers) and Metastasis and carcinoma case studies (3 papers). Ming Ouyang collaborates with scholars based in China, United States and Hong Kong. Ming Ouyang's co-authors include Chengzhi Zhou, Jiexia Zhang, Nanshan Zhong, Ming Liu, Jun Xu, Yinyin Qin, Zhanhong Xie, Xinqing Lin, Shiyue Li and Liqiang Wang and has published in prestigious journals such as ACS Applied Materials & Interfaces, International Journal of Cancer and Frontiers in Pharmacology.

In The Last Decade

Ming Ouyang

27 papers receiving 330 citations

Peers

Countries citing papers authored by Ming Ouyang

Since Specialization

Citations

This map shows the geographic impact of Ming Ouyang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming Ouyang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming Ouyang more than expected).

Fields of papers citing papers by Ming Ouyang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming Ouyang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming Ouyang. The network helps show where Ming Ouyang may publish in the future.

Co-authorship network of co-authors of Ming Ouyang

This figure shows the co-authorship network connecting the top 25 collaborators of Ming Ouyang. A scholar is included among the top collaborators of Ming Ouyang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming Ouyang. Ming Ouyang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China 2024 ·Frontiers in Pharmacology ·W.J. Lang, (unknown), Wenwen Zhang, (unknown), (unknown), Ming Ouyang	0
2	Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System 2024 ·Clinical Drug Investigation ·W.J. Lang, (unknown), Bei Huang, (unknown), (unknown), (unknown), Ming Ouyang	7
3	Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system 2024 ·Expert Review of Pharmacoeconomics & Outcomes Research ·W.J. Lang, (unknown), (unknown), Ming Ouyang	2
4	Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China 2024 ·International Journal of Clinical Pharmacy ·W.J. Lang, (unknown), (unknown), Yufei Pan, (unknown), Ming Ouyang, (unknown)	5
5	microRNA-181a-5p impedes the proliferation, migration, and invasion of retinoblastoma cells by targeting the NRAS proto-oncogene 2022 ·Clinics ·Ming Ouyang, (unknown), (unknown), (unknown)	14
6	The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research 2022 ·Frontiers in Oncology ·(unknown), (unknown), (unknown), Xinqing Lin, Xiaohong Xie, Haiyi Deng, Jianhui Wu, Maolin Zhou, (unknown), Zhanhong Xie, Ming Liu, Ming Ouyang, Yinyin Qin, Chunxia Su, Chengzhi Zhou	11
7	Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study 2022 ·Translational Lung Cancer Research ·Xinqing Lin, Haiyi Deng, Tianqing Chu, Likun Chen, (unknown), (unknown), Xiaohong Xie, Yinyin Qin, Ming Liu, Zhanhong Xie, Ming Ouyang, Shiyue Li, Yong Song, Francesco Petrella, Marko Jakopović, Nikolaos Tsoukalas, Piergiorgio Solli, Taichiro Goto, (unknown), Chengzhi Zhou	19
8	Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung 2021 ·Frontiers in Pharmacology ·(unknown), Fei Wang, Yinyin Qin, (unknown), Zhanhong Xie, Ming Liu, Ming Ouyang, (unknown), Yingying Gu, Shiyue Li, (unknown), Rongrong Chen, Chengzhi Zhou	11
9	Management of nonbacterial thrombotic endocarditis (NBTE) in advanced non-small cell lung cancer (NSCLC) patients with driver mutation: two case reports 2021 ·Annals of Palliative Medicine ·Zhanhong Xie, Ran Zhong, Xinqing Lin, Xiaohong Xie, Ming Ouyang, Ming Liu, Yinyin Qin, Jiexia Zhang, Chengzhi Zhou	2
10	Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer 2021 ·Frontiers in Oncology ·Xiaohong Xie, Liqiang Wang, (unknown), (unknown), Yinyin Qin, Xinqing Lin, Zhanhong Xie, Ming Liu, Ming Ouyang, Shiyue Li, Chengzhi Zhou	27
11	A first case report of clinical response to targeted therapy in a patient with primary myoepithelial carcinoma of the lung harboring EGFR exon 19 deletion 2020 ·Diagnostic Pathology ·Xiaohong Xie, Xinqing Lin, Ming Liu, Yinyin Qin, Ming Ouyang, Shiyue Li, Yingying Gu, Shuyin Chen, Jianxing Xiang, Chengzhi Zhou	3
12	Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma 2020 ·Orphanet Journal of Rare Diseases ·Xiaohong Xie, Liqiang Wang, Yinyin Qin, Xinqing Lin, Zhanhong Xie, Ming Liu, Jiexia Zhang, Ming Ouyang, Jun Liu, Yingying Gu, Shiyue Li, Chengzhi Zhou	33
13	The clinical analysis of pulmonary lymphoepithelioma-like carcinoma with epithelioid granuloma 2020 ·Translational Cancer Research ·(unknown), Chengzhi Zhou, Guofeng Wu, Wei‐jie Guan, Guosheng Deng, Zheng Zhu, Xinqing Lin, Xiaohong Xie, Zhanhong Xie, Jiexia Zhang, Ming Ouyang, Nanshan Zhong, Shiyue Li, Yinyin Qin	1
14	<p>Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2–3 After Progression of Second-Line or Later-Line Treatment</p> 2020 ·Cancer Management and Research ·(unknown), Fei Wang, (unknown), Yinyin Qin, Zhanhong Xie, Jiexia Zhang, Ming Ouyang, Chengzhi Zhou	11
15	Successful therapy with bevacizumab combined with corticosteroids for crizotinib-induced interstitial lung disease 2019 ·Angiogenesis ·Xiaohong Xie, Bingpeng Guo, Xinqing Lin, Yinyin Qin, Ming Ouyang, Shiyue Li, Chengzhi Zhou	4
16	Worldwide malaria incidence and cancer mortality are inversely associated 2017 ·Infectious Agents and Cancer ·Qin Li, Changzhong Chen, Lili Chen, Rui Xue, Ming Ouyang, Chengzhi Zhou, Siting Zhao, Zhengxiang He, Yu Xia, Jianxing He, Pinghua Liu, Nanshan Zhong, Xiaoping Chen	34
17	Fatal interstitial lung disease associated with icotinib. 2014 ·Europe PMC (PubMed Central) ·Jiexia Zhang, Yangqing Zhan, Ming Ouyang, Yinyin Qin, Chengzhi Zhou, Rongchang Chen	4
18	Insights into the Interfacial Properties of Low-Voltage CuPc Field-Effect Transistor 2013 ·ACS Applied Materials & Interfaces ·Yaorong Su, Ming Ouyang, Pengyi Liu, Zhi Luo, Weiguang Xie, Jianbin Xu	18
19	ERM stable knockdown by siRNA reduced in vitro migration and invasion of human SGC-7901 cells 2011 ·Biochimie ·Ming Ouyang, Hongrui Liu, Yu Zhang, (unknown), Qing Yang	20
20	Detection of epidermal growth factor receptor mutations in plasma by mutant‐enriched PCR assay for prediction of the response to gefitinib in patients with non‐small‐cell lung cancer 2009 ·International Journal of Cancer ·(unknown), Ming Liu, Chengzhi Zhou, Jiexia Zhang, Ming Ouyang, Nanshan Zhong, Jun Xu	87

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact